Sculptor Capital LP bought a new position in shares of Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 250,000 shares of the company's stock, valued at approximately $2,490,000. Sculptor Capital LP owned about 1.12% of Oaktree Acquisition Corp. III Life Sciences at the end of the most recent quarter.
Other institutional investors and hedge funds have also made changes to their positions in the company. Lighthouse Investment Partners LLC bought a new stake in shares of Oaktree Acquisition Corp. III Life Sciences during the fourth quarter worth $3,039,000. Shaolin Capital Management LLC bought a new stake in shares of Oaktree Acquisition Corp. III Life Sciences during the fourth quarter worth $5,478,000. AQR Arbitrage LLC bought a new position in shares of Oaktree Acquisition Corp. III Life Sciences during the 4th quarter worth $19,743,000. Finally, K2 Principal Fund L.P. bought a new stake in shares of Oaktree Acquisition Corp. III Life Sciences in the fourth quarter valued at about $1,945,000.
Oaktree Acquisition Corp. III Life Sciences Price Performance
Shares of OACC stock traded up $0.03 on Tuesday, hitting $10.48. The stock had a trading volume of 238 shares, compared to its average volume of 98,509. The business has a 50 day moving average price of $10.24. Oaktree Acquisition Corp. III Life Sciences has a one year low of $9.95 and a one year high of $10.85.
Oaktree Acquisition Corp. III Life Sciences Company Profile
(
Free Report)
Oaktree Acquisition Corp. III Life Sciences is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 1995 and is headquartered in Los Angeles, CA.
Recommended Stories
Before you consider Oaktree Acquisition Corp. III Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oaktree Acquisition Corp. III Life Sciences wasn't on the list.
While Oaktree Acquisition Corp. III Life Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
